Massimo Federico

26.9k total citations · 4 hit papers
288 papers, 12.0k citations indexed

About

Massimo Federico is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Massimo Federico has authored 288 papers receiving a total of 12.0k indexed citations (citations by other indexed papers that have themselves been cited), including 196 papers in Pathology and Forensic Medicine, 127 papers in Oncology and 75 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Massimo Federico's work include Lymphoma Diagnosis and Treatment (185 papers), Viral-associated cancers and disorders (71 papers) and Chronic Lymphocytic Leukemia Research (57 papers). Massimo Federico is often cited by papers focused on Lymphoma Diagnosis and Treatment (185 papers), Viral-associated cancers and disorders (71 papers) and Chronic Lymphocytic Leukemia Research (57 papers). Massimo Federico collaborates with scholars based in Italy, United States and United Kingdom. Massimo Federico's co-authors include Stefano Luminari, Julie M. Vose, Bertrand Coiffier, Luigi Marcheselli, Randy D. Gascoyne, Kensei Tobinai, Emanuele Zucca, Joseph M. Connors, Steven T. Rosen and Martin Dreyling and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Massimo Federico

279 papers receiving 11.8k citations

Hit Papers

Revised Response Criteria for Malignant Lymphoma 2007 2026 2013 2019 2007 2011 2009 2014 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Revised Response Criteria for Malignant Lymphoma
    2007 3.2k citations Steven T. Rosen, Julie M. Vose et al. Journal of Clinical Oncology profile →
  2. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts
    2011 673 citations Claudia Cirilli, Massimo Federico et al. profile →
  3. Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
    2009 506 citations Massimo Federico, Monica Bellei et al. Journal of Clinical Oncology profile →
  4. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2014 324 citations Massimo Federico, Martin Hutchings et al. Annals of Oncology profile →

Peers

Massimo Federico
Comparison fields: 5 of 136
  • Pathology and Forensic Medicine 8.0k
  • Oncology 5.5k
  • Pulmonary and Respiratory Medicine 2.5k
  • Neurology 2.3k
  • Genetics 2.1k
Replace Franco Cavalli with:
Franco Cavalli Switzerland
Catherine Thiéblemont France
Martin Dreyling Germany
Corinne Haïoun France
Won Seog Kim South Korea
Emanuele Zucca Switzerland
Cheolwon Suh South Korea
Joachim Yahalom United States
Pier Luigi Zinzani Italy
Yoshihiro Matsuno Japan
Franco Cavalli Switzerland View profile →
Citations per field, relative to Massimo Federico
Massimo Federico · 1×
Citations per year, relative to Massimo Federico
Massimo Federico · 1×

Countries citing papers authored by Massimo Federico

Since Specialization
Citations

This map shows the geographic impact of Massimo Federico's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Massimo Federico with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Massimo Federico more than expected).

Fields of papers citing papers by Massimo Federico

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Massimo Federico. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Massimo Federico. The network helps show where Massimo Federico may publish in the future.

Co-authorship network of co-authors of Massimo Federico

This figure shows the co-authorship network connecting the top 25 collaborators of Massimo Federico. A scholar is included among the top collaborators of Massimo Federico based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Massimo Federico. Massimo Federico is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network
2023 ·Blood Advances ·Greg Hapgood, Monica Civallero, (unknown), Julie M. Vose, (unknown), Ranjana H. Advani, Stefano Pileri, Martina Manni, Steven M. Horwitz, Francine M. Foss, Felicitas Hitz, John Radford, Iván Dlouhy, Carlos Chiattone, (unknown), Tetiana Skrypets, Arnon Nagler, Judith Trotman, Stefano Luminari, Massimo Federico
1
2
Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project
2021 ·Blood ·Ranjana H. Advani, Tetiana Skrypets, Monica Civallero, Michael A. Spinner, Martina Manni, Won-Seog Kim, Andrei R. Shustov, Steven M. Horwitz, Felicitas Hitz, María Elena Cabrera, Iván Dlouhy, José Vassallo, Stefano Pileri, Giorgio Inghirami, Silvia Montoto, Umberto Vitolo, John Radford, Julie M. Vose, Massimo Federico
60
3
Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium
2020 ·Blood ·Angie Mae Rodday, Susan K. Parsons, (unknown), Ranjana H. Advani, Massimo Federico, Jonathan W. Friedberg, Andrea Gallamini, David Hodgson, Peter Hoskin, Martin Hutchings, Peter Johnson, Kara M. Kelly, Brian K. Link, John Radford, Pier Luigi Zinzani, James R. Cerhan, John Raemaekers, Andrew M. Evens
3
4
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma
2020 ·Hematological Oncology ·Raffaella Marcheselli, Alessia Bari, Tamar Tadmor, Luigi Marcheselli, Maria Christina Cox, (unknown), Angela Ferrari, Luca Baldini, Paolo G. Gobbi, Ilana Levy, Giuseppe Pugliese, Massimo Federico, Aaron Polliack, Samantha Pozzi, Stefano Sacchi
5
5
Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study
2020 ·Clinical Lymphoma Myeloma & Leukemia ·Frederick Lansigan, Sarah McCue Horwitz, Lauren Pinter‐Brown, Kenneth R. Carson, Andrei R. Shustov, Steven T. Rosen, Barbara Pro, Eric D. Hsi, Massimo Federico, Christian Gisselbrecht, Marc Schwartz, Lisa A. Bellm, Mark Acosta, Francine M. Foss
9
6
Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL)
2019 ·British Journal of Haematology ·(unknown), Antonella Anastasia, Annalisa Chiarenza, Luigi Marcheselli, Federica Cavallo, Sara Rattotti, Barbara Botto, Angela Ferrari, Luca Nassi, Chiara Pagani, (unknown), Luca Arcaini, Massimo Federico, Giuseppe Rossi, (unknown)
18
7
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas
2019 ·American Journal of Hematology ·Francine M. Foss, Steven M. Horwitz, Monica Civallero, Monica Bellei, Luigi Marcheselli, Won Seog Kim, María Elena Cabrera, Iván Dlouhy, Arnon Nagler, Ranjana H. Advani, Emanuela Anna Pesce, Young Hyeh Ko, Silvia Montoto, Carlos Chiattone, Alison J. Moskowitz, Michele Spina, Marina Cesaretti, Irène Biasoli, Massimo Federico
38
8
Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study
2018 ·Blood ·Anne‐Ségolène Cottereau, Annibale Versari, Stefano Luminari, Jehan Dupuis, Loïc Chartier, Olivier Casasnovas, Alina Berriolo-Riedinger, Massimo Menga, Corinne Haïoun, Hervé Tilly, Vittoria Tarantino, Massimo Federico, Gilles Salles, Judith Trotman, Michel Meignan
52
9
The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project
2018 ·Haematologica ·Monica Bellei, Francine M. Foss, Andrei R. Shustov, Steven M. Horwitz, Luigi Marcheselli, Won Seog Kim, María Elena Cabrera, Iván Dlouhy, Arnon Nagler, Ranjana H. Advani, Emanuela Anna Pesce, Young Hyeh Ko, (unknown), Silvia Montoto, Carlos Chiattone, Alison J. Moskowitz, Michele Spina, Irène Biasoli, Martina Manni, Massimo Federico
88
10
Outcome of Patients with Gamma Delta T Cell Lymphomas: Analysis of 1429 Cases Registered in the Prospective T-Cell Project
2017 ·Blood ·Francine M. Foss, Steven M. Horwitz, Monica Bellei, Martina Manni, Vittoria Tarantino, Andrei R. Shustov, Iván Dlouhy, María Elena Cabrera, Won Seog Kim, Felicitas Hitz, Raúl Gabus, Antonio Gutiérrez, (unknown), Umberto Vitolo, Francesco Merli, Veronika Ballová, Andrew Davies, Maria Giuseppina Cabras, Francesco Di Raimondo, Massimo Federico
3
11
A pooled data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL): Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in non-Hodgkin lymphoma (NHL)
2016 ·Annals of Oncology ·Roberto Santi, Manuela Ceccarelli, Chiara Monagheddu, Andrea Evangelista, (unknown), Federico Monaco, Massimo Federico, Umberto Vitolo, (unknown), Maria Giuseppina Cabras, Michele Spina, Luca Baldini, Carola Boccomini, Annalisa Chiappella, Alessia Bari, Stefano Luminari, Carlo Visco, Laura Contino, Giovannino Ciccone, Marco Ladetto
1
12
EPIDEMIOLOGICAL OVERVIEW OF HODGKIN LYMPHOMA ACROSS THE MEDITERRANEAN BASIN
2014 ·Mediterranean Journal of Hematology and Infectious Diseases ·Massimiliano Salati, Marina Cesaretti, (unknown), (unknown), Massimo Federico
30
13
The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: Results of a comparative analysis
2013 ·Leukemia Research ·Stefano Molica, Diana Giannarelli, Massimo Gentile, Giovanna Cutrona, Nicola Di Renzo, Francesco Di Raimondo, Antonino Neri, Massimo Federico, Manlio Ferrarini, Fortunato Morabito
5
14
Watchful Waiting in Low–Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database
2012 ·Journal of Clinical Oncology ·Philippe Solal‐Céligny, Monica Bellei, Luigi Marcheselli, Emanuela Anna Pesce, Stefano Pileri, Peter McLaughlin, Stefano Luminari, Barbara Pro, Silvia Montoto, Andrés J.M. Ferreri, Éric Deconinck, Nöel Milpied, Leo I. Gordon, Massimo Federico
88
15
Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.
2012 ·PubMed ·Laura Cortesi, Elisabetta De Matteis, Claudia Cirilli, Luigi Marcheselli, (unknown), Massimo Federico
7
16
An Increased Number of Individuals with Clinically Recognized Monoclonal B-Cell Lymphocytosis Characterizes a Recent Database of Chronic Lymphocytic Leukemia Rai Stage 0
2012 ·Acta Haematologica ·Stefano Molica, Massimo Gentile, Francesca Romana Mauro, Maura Brugiatelli, Massimo Federico, Isabella Sperduti, Antonino Neri, Manlio Ferrarini, Robin Foà, Fortunato Morabito
3
17
patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial
2011 ·Annals of Oncology ·Stefano Luminari, Antonella Montanini, Dolores Caballero, Serge Bologna, Michael Notter, Martin J.S. Dyer, Annalisa Chiappella, Javier Briones, Mario Petrini, (unknown), L. Kayitalire, Massimo Federico, (unknown)
1
18
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study
2008 ·Haematologica ·Stefano Sacchi, Luigi Marcheselli, Alessia Bari, Raffaella Marcheselli, Samantha Pozzi, P. Gobbi, F. Angrilli, Maura Brugiatelli, Pellegrino Musto, Massimo Federico
29
19
Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma.
2001 ·PubMed ·(unknown), Massimo Federico, Umberto Vitolo, Carola Boccomini, Daniele Vallisa, Luca Baldini, Mario Petrini, Serena Rupoli, Francesco Di Raimondo, (unknown), (unknown), Antonio Tabilio, Giuseppe Saglio, (unknown), Maura Brugiatelli, Giuseppe Dastoli
62
20
Castleman's lymphoadenopathy: twenty years of observation. II. Generalized form.
1982 ·PubMed ·T Artusi, Goretta Bonacorsi, A Saragoni, (unknown), (unknown), Massimo Federico, (unknown)
9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Franco Cavalli Breakdown of academic impact, for papers by Catherine Thiéblemont Breakdown of academic impact, for papers by Martin Dreyling Breakdown of academic impact, for papers by Corinne Haïoun Breakdown of academic impact, for papers by Won Seog Kim Breakdown of academic impact, for papers by Emanuele Zucca Breakdown of academic impact, for papers by Cheolwon Suh Breakdown of academic impact, for papers by Joachim Yahalom Breakdown of academic impact, for papers by Pier Luigi Zinzani Breakdown of academic impact, for papers by Yoshihiro Matsuno
Rankless by CCL
2026